“Global tissue diagnostics market is expected to reach $8.24 Bn by 2029”, says Visiongain

08 January 2020
Pharma

Visiongain’s new report the Tissue Diagnostics Market Report : Forecasts by Product (Consumables, Instruments), by Product (Immunohistochemistry, in Situ Hybridization, Digital Pathology, Others), by Disease (Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-Small Cell Lung Cancer, Others), by End User (Hospitals, Research Labs, Pharmaceutical Companies, Research Organizations), plus analysis of leading companies operating in the global tissue diagnostics market.

In 2019, the global tissue diagnostics market was valued at $4.09 billion and is expected to reach $8.24 billion by 2029 at a CAGR of 7.2% over the forecast period. Rising cancer prevalence all over the world, expanding healthcare infrastructure in developing countries, growing healthcare diagnostics affordability, technological advancement in imaging, and growth in personalized therapeutics is expected to increase tissue diagnostics market expansion over the projected period.

Improving healthcare infrastructure in developing countries such as India, China, Indonesia, Singapore, Malaysia, South Korea, Brazil, and Colombia is expected to encourage healthcare service providers to expand their facilities in these countries. Additionally, increasing disposable income followed by increasing healthcare spending has increased market penetration of tissue diagnostics over the past few years and the trend is expected to continue over the course of time.

Technological advancement in tissue diagnostics is expected to open avenues in the global healthcare industry. For instance, in 2018, According to University of Illinois, a new microscope system can image living tissue in real time and in molecular detail, without any chemicals or dyes. Some other prominent technologies innovated in 2017 are a Mass Spec Pen To Rapidly Identify Cancer, Paper Point-of-Care Zika Test, Transparent Tissues for Pathological Diagnosis, Paper-based Electrochemical Diagnostics, Microfluidic Chip to Predict Preterm Birth, Smartphone TRI Analyzer, and Wearable Sweat Sensor.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Ophthalmic Devices Market Report 2022-2032

The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.

19 April 2022

Read

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2022-2032

The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet

13 April 2022

Read

Visiongain Publishes Pharmaceutical Contract Manufacturing Market Report 2022-2032

The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.

13 April 2022

Read

Visiongain Publishes Vaccine Sales Market Report 2022-2032

Rising epidemic potential, a growing emphasis on therapeutic vaccines, and new markets are projected to provide considerable growth prospects for vaccine providers.

30 March 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever